NOVOCURE LTD
NVCRNASDAQTrading Snapshot
- Day Range
- $13.85 – $14.64
- 52-Week Range
- $9.82 – $21.45
- Volume (shares)
- 2,383,079
- Avg Volume (shares)
- —
- Shares Outstanding
- 116.5M
- Next Earnings
- 2026-10-29
Fundamentals Snapshot
- Annual Revenue
- $655M
- Last Q Revenue
- $184M
- P/E Ratio
- —
- P/S Ratio
- 2.4x
- EPS (TTM)
- $-1.31
- Dividend Yield
- —
- Dilution (1yr)
- +3.4%
NOVOCURE LTD
NVCR
StockOtter · stockotter.spaceAbout NOVOCURE LTD
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure's Tumor Trea
NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) Head to Head Contrast
Ambu A/S (OTCMKTS:AMBBY - Get Free Report) and NovoCure (NASDAQ: NVCR - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of thei
Novocure: A Mispriced Cash-Generating Biotech With Upside Potential
NovoCure is undervalued at a $1.66B market cap, with its pipeline and FDA-approved products not fully reflected in its price. NVCR's revenue grew 16% YoY to $183.58M, with international sales and patient adoption acceler
Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)
NeurAxis (NASDAQ: NRXS - Get Free Report) and NovoCure (NASDAQ: NVCR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strengt
Critical Survey: Medline (NASDAQ:MDLN) & NovoCure (NASDAQ:NVCR)
NovoCure (NASDAQ: NVCR - Get Free Report) and Medline (NASDAQ: MDLN - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their pro
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable